BAX:NYE-Baxter International Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NYE

Last Closing Price

USD 73.03

Change

0.00 (0.00)%

Market Cap

USD 36.77B

Volume

2.07M

Avg Analyst Target

USD 94.77 (+29.77%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Baxter International Inc (BAX) Stock Analysis:
Based on the Baxter International Inc stock forecasts from 10 analysts, the average analyst target price for Baxter International Inc is USD 94.77 over the next 12 months. Baxter International Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Baxter International Inc is Neutral, which is based on 6 positive signals and 7 negative signals. At the last closing, Baxter International Inc’s stock price was USD 73.03. Baxter International Inc’s stock price has changed by +0.33% over the past week, -4.46% over the past month and -12.91% over the last year.

About

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-15 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BDX Becton Dickinson and Company

N/A

USD70.82B 43.15 18.29
ALC Alcon AG

N/A

USD34.74B 92.96 20.45
RMD ResMed Inc

N/A

USD29.29B 37.15 24.35
WST West Pharmaceutical Services I..

N/A

USD22.59B 34.01 24.92
VAR Varian Medical Systems, Inc

N/A

USD16.26B 58.40 32.91
COO The Cooper Companies Inc

N/A

USD16.16B 17.41 23.27
TFX Teleflex Incorporated

N/A

USD13.06B 27.08 16.47
HRC Hill-Rom Holdings Inc

N/A

USD10.30B 41.92 21.82
ATR AptarGroup Inc

N/A

USD7.05B 32.59 14.22
NVST Envista Holdings Corporation

N/A

USD6.76B 21.72 16.98

ETFs Containing BAX

Symbol Name Weight Mer Price(Change) Market Cap
DX2E:XETRA Xtrackers - S&P Global In.. 3.97 % 0.60 %

N/A

USD0.40B
DX2E:F Xtrackers - S&P Global In.. 3.97 % 0.60 %

N/A

USD0.40B
PBI Pitney Bowes Inc 0.00 % 0.00 %

N/A

USD0.79B
XHE SPDR Series Trust - SPDR .. 0.00 % 0.35 %

N/A

USD0.47B
RBUS Nationwide Risk-Based U.S.. 0.00 % 0.30 %

N/A

USD0.11B
XSGI:LSE Xtrackers - S&P Global In.. 0.00 % 0.60 %

N/A

USD0.40B
XGID:LSE Xtrackers S&P Global Infr.. 0.00 % 0.60 %

N/A

USD0.40B
MVUS:PA Ossiam IRL ICAV - Ossiam .. 0.00 % 0.65 %

N/A

N/A
SPMV:PA Ossiam IRL ICAV - Ossiam .. 0.00 % 0.65 %

N/A

N/A
OSX2:XETRA Ossiam Lux - Ossiam US Mi.. 0.00 % 0.65 %

N/A

N/A
ASPY ASYMshares® ASYMmetric 5.. 0.00 % 0.95 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.92% 72% C- 46% F
Dividend Return 0.33% 50% F 21% F
Total Return -14.60% 72% C- 45% F
Trailing 12 Months  
Capital Gain -12.91% 56% F 46% F
Dividend Return 1.34% 78% C+ 27% F
Total Return -11.58% 56% F 42% F
Trailing 5 Years  
Capital Gain 26.83% 18% F 63% D
Dividend Return 7.61% 63% D 25% F
Total Return 34.44% 18% F 59% F
Average Annual (5 Year Horizon)  
Capital Gain 6.51% 21% F 54% F
Dividend Return 1.16% 55% F 28% F
Total Return 7.68% 21% F 48% F
Risk Return Profile  
Volatility (Standard Deviation) 12.20% 89% B+ 77% C+
Risk Adjusted Return 62.91% 53% F 75% C
Market Capitalization 36.77B 94% A 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 34.96 47% F 17% F
Price/Book Ratio 4.05 18% F 19% F
Price / Cash Flow Ratio 16.55 53% F 23% F
EV/EBITDA 20.62 36% F 18% F
Management Effectiveness  
Return on Equity 14.51% 76% C 64% D
Return on Invested Capital 7.35% 67% D+ 57% F
Return on Assets 4.88% 72% C- 71% C-
Debt to Equity Ratio 188.18% 7% F 19% F
Technical Ratios  
Dividend Yield 1.59% 90% A- 12% F
Short Ratio 1.91 100% A+ 53% F
Short Percent 1.62% 71% C- 69% D+
Beta 0.60 83% B 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector